h
uman
plasma
sourc
clot
factor
concentr
use
treatment
bleed
disord
caus
coagul
factor
defici
disord
includ
hemophilia
factor
f
viii
hemophilia
b
f
ix
von
willebrand
diseas
von
willebrand
factor
vwf
rarer
disord
fibrinogen
fxiii
fx
defici
number
acquir
bleed
disord
von
willebrand
diseas
rare
bleed
disord
acquir
bleed
plasmaderiv
clot
factor
concentr
recombin
concentr
avail
fourfactor
prothrombin
complex
concentr
kcentra
beriplex
pn
europ
csl
behr
marburg
germani
recent
approv
unit
state
revers
warfarin
effort
prevent
transmiss
infecti
agent
acceler
recognit
human
immunodefici
viru
hiv
transmiss
hemophilia
patient
identif
hepat
c
viru
hcv
thereaft
substanti
clinic
evid
lack
transmiss
lipid
membraneenvelop
virus
hepat
b
hbv
hcv
hiv
use
solventdeterg
sd
treatment
nonenvelop
virus
includ
hepat
viru
hav
parvoviru
present
addit
challeng
inactiv
techniqu
germani
pasteur
heat
hour
stabil
aqueou
solut
develop
late
clot
factor
concentr
dedic
viru
reduct
method
fviii
vwf
concentr
licens
proven
case
viru
transmiss
report
recent
prion
transmiss
becom
concern
manufactur
process
evolv
includ
multipl
step
prevent
transmiss
known
emerg
bloodborn
pathogen
object
review
examin
current
method
prevent
pathogen
transmiss
via
plasmaderiv
clot
factor
concentr
stateoftheart
select
plasma
effect
pathogen
inactiv
remov
manufactur
process
clot
factor
concentr
deriv
pool
consist
larg
number
donat
fraction
pool
size
vari
depend
size
vessel
use
pool
plasma
batch
final
product
includ
sever
fraction
pool
donor
screen
test
donat
fraction
pool
first
step
product
safeti
follow
pathogen
inactiv
andor
remov
ie
reduct
manufactur
sourc
plasma
apheresi
commonli
come
compens
donor
recov
plasma
whole
blood
donor
compens
cash
manufactur
process
clot
factor
concentr
start
materi
safeti
record
virtual
ident
european
medicin
agenc
ema
publish
guidelin
focus
safeti
plasmaderiv
product
fourth
version
detail
measur
necessari
prevent
transmiss
virus
recipi
plasmaderiv
product
measur
includ
select
donor
screen
donat
plasma
pool
marker
infect
known
virus
manufactur
process
high
capac
inactiv
andor
remov
virus
select
step
valid
viru
reduct
capac
guidelin
state
effect
step
inactivationremov
wide
rang
virus
divers
physicochem
characterist
requir
manufactur
ema
world
health
organ
recommend
two
distinct
step
complementari
mode
action
use
help
ensur
viru
surviv
step
inactiv
andor
remov
step
least
one
step
inactiv
remov
nonenvelop
virus
ema
guidelin
state
manufactur
process
contain
step
reliabl
inactiv
andor
remov
wide
rang
envelop
nonenvelop
virus
addit
manufactur
step
reliabl
contribut
inactiv
andor
remov
virus
second
step
might
requir
unit
state
manufactur
plasmaderiv
product
must
includ
least
one
effect
step
remov
andor
inactiv
virus
care
valid
requir
inactiv
remov
step
variou
method
viru
inactiv
remov
use
concentr
avail
mani
countri
present
tabl
estim
potenti
specif
step
reduc
prion
infect
ema
recommend
evalu
studi
prion
establish
process
product
clot
factor
concentr
shown
reduc
prion
infect
biolog
product
includ
recombin
clot
factor
product
requir
undergo
complementari
pathogen
reduct
step
analog
plasmaderiv
clot
factor
concentr
valid
requir
also
similar
recombin
protein
safeti
focu
plasmaderiv
product
receiv
greater
attent
histori
viru
transmiss
howev
potenti
viru
contamin
issu
biolog
product
adher
strict
donor
select
criteria
screen
donat
effect
reduc
viru
load
inactiv
andor
remov
plasma
pool
fraction
current
screen
test
abl
detect
prion
infect
donor
although
experiment
blood
test
prion
infect
recent
develop
precaut
ema
us
food
drug
administr
fda
recommend
deferr
donor
risk
develop
creutzfeldtjakob
diseas
cjd
variant
vcjd
use
seri
question
exclud
donat
risk
pool
process
although
screen
viral
marker
serolog
viru
nucleic
acid
nucleic
acid
test
nat
ensur
nearli
plasma
unit
enter
product
free
hbv
hcv
hiv
inactiv
remov
step
necessari
reduc
virus
may
enter
plasma
pool
window
period
marker
detect
estim
window
serolog
test
could
result
identif
plasma
pool
contain
hivinfect
unit
one
five
contain
hbvor
hcvinfect
unit
particular
nat
assay
pool
configur
nat
shown
decreas
diagnost
window
day
day
hbv
day
hcv
therebi
decreas
amount
viru
enter
plasma
pool
fraction
reduc
residu
risk
decreas
number
potenti
infect
unit
pool
concentr
viru
howev
screen
suffici
ensur
safeti
product
test
limit
detect
target
specif
addit
size
minipool
nat
impact
effect
plasma
industri
develop
two
set
standard
plasma
protein
therapeut
associ
intern
qualiti
plasma
program
focus
donor
center
manag
second
standard
known
qualiti
standard
excel
assur
leadership
qseal
address
manufactur
part
qseal
inventori
hold
standard
introduc
address
window
period
describ
previous
standard
allow
remov
previous
donat
unit
donor
subsequ
test
posit
viru
ie
remov
window
donat
highli
effect
reduc
risk
donat
infect
donor
nonreact
serolog
nat
time
donat
enter
manufactur
pool
inventori
hold
quarantin
would
interdict
infecti
unit
nat
window
period
donor
return
effect
hold
relat
larg
number
donor
donat
frequent
sourc
plasma
donat
use
manufactur
equival
donat
transfus
term
pathogen
safeti
addit
manufactur
standard
qseal
includ
qualifi
donor
viru
marker
standard
ident
intern
qualiti
plasma
program
valid
product
step
necessari
estim
pathogen
inactiv
andor
remov
capac
provid
confid
safeti
plasmaderiv
clot
factor
product
viru
reduct
capac
manufactur
process
test
dedic
laboratori
use
valid
scaleddown
version
manufactur
process
employ
process
intermedi
spike
high
titer
appropri
viru
determin
viru
reduct
factor
achiev
virus
select
valid
close
resembl
pose
greatest
threat
contamin
hepat
virus
hiv
virus
practic
cell
cultur
system
avail
thu
specif
model
virus
use
select
virus
includ
differ
genom
size
envelop
characterist
repres
wide
rang
physicochem
properti
virus
allow
manufactur
fulli
test
viru
reduct
capac
manufactur
process
provid
indirect
evid
reduc
virus
gener
reduct
factor
greater
log
gener
consid
effect
viru
reduct
factor
achiev
individu
inactiv
andor
remov
step
present
tabl
remov
prion
plasmaderiv
product
evalu
similarli
viru
valid
studi
base
valid
scaleddown
version
manufactur
process
prion
detect
quantit
anim
bioassay
consid
appropri
although
vitro
method
western
blot
assay
enzymelink
immunosorb
assay
conformationdepend
immunoassay
also
use
detect
misfold
prion
protein
pasteur
heat
protein
aqueou
stabil
solut
hour
inactiv
lipid
membraneenvelop
rang
nonenvelop
virus
tabl
coagul
factor
heat
sensit
therefor
stabil
usual
sugar
amino
acid
acet
ad
preserv
protein
integr
remov
pathogen
inactiv
homogen
temperatur
throughout
pasteur
must
valid
temperatur
map
techniqu
studi
inactiv
hiv
hav
pasteur
fviii
vwf
concentr
demonstr
viru
reduct
factor
least
least
log
respect
tabl
lipid
membran
envelop
virus
disrupt
sd
mixtur
therebi
prevent
bind
infect
cell
virus
organ
solvent
eg
tri
nbutyl
phosphat
combin
nonion
deterg
polyethylen
glycol
octylphenyl
ether
triton
polysorb
typic
use
treatment
sd
compound
remov
chromatographi
oil
extract
product
solut
filter
remov
virus
entrap
particl
thu
protect
exposur
sd
homogen
mix
mainten
consist
temperatur
throughout
incub
must
valid
plasma
protein
therapeut
associ
member
compani
compil
data
effect
viru
inactiv
sd
treatment
fviii
f
ix
intraven
immunoglobulin
intramuscular
immunoglobulin
viru
inactiv
evalu
studi
reflect
product
condit
well
variabl
significantli
beyond
process
specif
result
demonstr
product
class
process
temperatur
protein
concentr
ph
substanti
involv
viru
inactiv
contrast
concentr
sd
critic
significantli
specifi
process
fviii
vwf
concentr
sd
treatment
studi
demonstr
reduct
factor
log
hiv
sindbi
viru
sinv
prv
f
ix
concentr
reduct
factor
greater
log
hiv
sinv
vesicular
stomat
viru
bvdv
prv
import
limit
sd
treatment
specif
lipidenvelop
virus
report
patient
hemophilia
hav
infect
receiv
sdtreat
fviii
concentr
therefor
second
viru
reduct
step
requir
manufactur
plasmaderiv
product
close
gap
viru
safeti
plasmaderiv
concentr
lyophil
especi
treat
sd
subsequ
treat
dri
heat
inactiv
nonenvelop
virus
resist
sd
treatment
lyophil
confer
certain
degre
viru
inactiv
moistur
content
lyophil
product
undergo
dri
heat
treatment
kept
low
typic
residu
moistur
may
affect
product
stabil
although
higher
level
may
enhanc
inactiv
virus
dri
heat
treatment
lyophil
product
demonstr
favor
result
inactiv
relev
model
virus
hav
hbv
hcv
hiv
dri
heat
lyophil
fviii
product
hour
inactiv
wide
rang
virus
dri
heat
fviii
f
ix
concentr
reduc
risk
hcv
transmiss
addit
studi
demonstr
termin
dri
heat
lyophil
fviii
concentr
minut
inactiv
hav
hiv
detect
level
within
minut
retain
approxim
fviii
activ
wherea
heat
lyophil
fviii
vwf
concentr
minut
reduc
wide
array
virus
hiv
sinv
prv
reoviru
hav
log
although
reduc
dri
heat
valid
studi
reduct
factor
may
suffici
complet
inactiv
viru
load
final
product
asymptomat
infect
detect
patient
receiv
fviii
concentr
treat
hour
one
drawback
lyophil
addit
stabil
coagul
factor
remov
water
also
stabil
potenti
virus
product
ad
water
vapor
lyophil
product
heat
higher
level
viru
inactiv
achiev
equival
temperatur
vapor
heat
lyophil
product
target
envelop
nonenvelop
virus
demonstr
inactiv
hepat
virus
hiv
lyophil
vapor
heat
inactiv
approxim
log
hav
spike
fviii
concentr
within
hour
similarli
reduc
hav
titer
f
ix
concentr
within
hour
among
patient
hemophilia
receiv
vaporh
f
ix
infus
none
develop
marker
infect
hcv
hiv
month
followup
suggest
vapor
heattreat
concentr
may
associ
low
risk
viral
infect
howev
vapor
heat
may
insuffici
inactiv
hbv
complet
depend
viru
load
start
materi
batch
relat
amount
product
given
patient
vaccin
hbv
report
four
hemophilia
patient
vaccin
hbv
becam
infect
hbv
receiv
vaporh
fviii
concentr
addit
viru
inactiv
virus
also
physic
remov
plasmaderiv
product
fraction
precipit
chromatographi
filtrat
tabl
plasma
fraction
mainli
consid
step
protein
purif
dedic
viru
reduct
step
except
pasteur
human
albumin
implement
manufactur
process
later
viru
valid
studi
show
fraction
reliabl
contribut
overal
viru
reduct
capac
plasmaderiv
protein
although
ethanol
precipit
wide
use
plasma
fraction
method
worldwid
use
product
coagul
factor
concentr
treatment
denatur
desir
protein
initi
cryoprecipit
mani
clot
factor
concentr
purifi
chromatograph
studi
robert
colleagu
purif
f
ix
concentr
use
metal
chelat
affin
chromatographi
reduc
polioviru
sinv
reduct
factor
log
respect
product
purifi
use
affin
chromatographi
mediat
antibodi
protein
interest
affin
chromatographi
use
purifi
fviii
concentr
result
reduct
factor
log
encephalomyocard
viru
log
sinv
log
porcin
parvoviru
ppv
model
viru
log
hav
purif
fviii
concentr
use
monoclon
antibodi
moab
affin
chromatographi
contribut
overal
viru
reduct
capabl
log
hiv
sinv
vesicular
stomat
viru
prv
pasteur
f
ix
concentr
moab
affin
chromatographi
alon
result
reduct
factor
least
log
envelop
virus
hiv
bvdv
prv
wnv
reduct
factor
log
nonenvelop
virus
hav
parvoviru
respect
import
consider
exist
reus
chromatographi
column
virus
adher
resin
complet
wash
therefor
equip
materi
must
sanit
valid
chemic
andor
physic
treatment
inactiv
remov
virus
ensur
crosscontamin
subsequ
batch
product
virus
may
remov
clot
factor
concentr
via
filtrat
employ
retent
filter
pore
smaller
viru
diamet
viru
filtrat
also
call
nanofiltr
filtrat
may
feasibl
product
contain
protein
compar
larger
size
virus
pore
size
filter
thu
filtrat
mainli
limit
smallermolecularweight
coagul
factor
eg
f
ix
fviii
howev
vwf
concentr
filter
pore
membran
result
reduct
factor
least
log
envelop
virus
hiv
bvdv
prv
although
filtrat
remov
larg
vwf
multim
well
filtrat
fviii
concentr
use
sequenti
filtrat
result
remov
envelop
hiv
bvdv
prv
nonenvelop
hav
ppv
virus
viru
filtrat
alon
result
viru
reduct
factor
least
log
combin
sd
chromatographi
viru
filtrat
yield
reduct
factor
least
log
test
virus
viru
filtrat
fxiii
concentr
use
filter
result
reduct
envelop
hiv
bvdv
prv
nonenvelop
hav
virus
least
log
reduct
nonenvelop
parvoviru
log
tabl
exampl
viru
reduct
achiev
addit
filtrat
step
safeti
studi
f
ix
concentr
final
viru
filtrat
step
ad
follow
fraction
chromatographi
sd
treatment
sequenti
filtrat
step
result
reduct
factor
least
log
hav
least
log
bvdv
filtrat
anoth
f
ix
concentr
use
two
filter
mean
pore
size
seri
effect
remov
envelop
nonenvelop
virus
appropri
margin
safeti
respect
bloodborn
virus
achiev
overal
viru
reduct
factor
clearli
exce
amount
viru
potenti
enter
manufactur
pool
europ
quantit
risk
assess
requir
estim
viru
particl
content
finish
product
determin
base
worst
case
scenario
viru
concentr
start
materi
amount
plasma
requir
produc
one
vial
divid
viru
reduct
factor
high
margin
safeti
document
fewer
one
viru
particl
per
million
dose
expect
base
steril
assur
level
respect
bacteria
mold
yeast
pharmacopoeia
worldwid
virus
replic
cellfre
medium
dissolv
final
product
applic
steril
assur
level
virus
conserv
transmiss
spongiform
encephalopathi
group
prionassoci
fatal
neurodegen
diseas
three
possibl
case
prion
transmiss
result
vcjd
one
probabl
case
asymptomat
infect
report
patient
unit
kingdom
receiv
nonleukoreduc
red
blood
cell
asymptomat
infect
individu
date
recipi
pool
plasmaderiv
product
develop
vcjd
howev
one
report
asymptomat
prion
detect
autopsi
hemophilia
patient
probabl
due
prioncontamin
fviii
concentr
prion
screen
test
current
unavail
donor
select
manufactur
process
prion
remov
import
request
ema
fda
restrict
plasma
donat
impos
mani
countri
plasmaderiv
protein
leukoreduc
plasma
prepar
decreas
risk
prion
transmiss
addit
manufactur
step
plasma
fraction
viru
remov
includ
precipit
chromatographi
filtrat
tabl
also
proven
efficaci
evalu
studi
inactiv
prion
plasmaderiv
clot
factor
concentr
possibl
need
techniqu
denatur
coagul
factor
appropri
clean
sanit
method
materi
equip
use
product
plasmaderiv
product
inactiv
remov
prion
protein
thu
batchtobatch
segreg
achiev
batchtobatch
contamin
exclud
emerg
microbi
pathogen
parasit
less
threat
steril
filtrat
combin
step
prepar
finish
product
remov
pathogen
howev
new
emerg
virus
must
assess
care
regard
potenti
impact
safeti
plasma
pool
fraction
final
product
new
emerg
virus
may
novel
zoonot
virus
encount
human
enter
new
geograph
area
previous
undiscov
anim
virus
cross
speci
barrier
enter
human
diseas
chain
eg
hiv
yellow
fever
viru
sever
acut
respiratori
syndrom
coronaviru
menangl
viru
hendra
viru
nipah
viru
hantavirus
monkeypox
viru
hepat
e
viru
detect
differ
region
world
consid
zoonosi
particular
genotyp
mainli
detect
domest
wild
pig
found
human
develop
countri
human
parvoviru
relat
parvovirus
identifi
cow
pig
primat
human
furthermor
new
viru
emerg
andor
reemerg
new
geograph
region
exampl
wnv
known
africa
middl
east
emerg
north
america
improv
diagnost
method
result
detect
previous
unknown
virus
consid
emerg
hcv
human
herpesviru
type
tt
viru
meet
challeng
epidemiolog
emerg
pathogen
donor
popul
potenti
infecti
viru
load
donat
asymptomat
incub
must
address
dilig
surveil
avail
inform
may
result
tempor
deferr
donor
base
geograph
risk
reach
high
load
infect
person
preval
viru
low
mani
region
contamin
plasma
pool
fraction
report
result
final
product
dna
howev
dna
current
product
undetect
lower
product
manufactur
possibl
thorough
screen
donor
test
donat
pathogen
may
associ
manufactur
process
coagul
factor
concentr
remov
andor
inactiv
low
level
dedic
viru
reduct
step
manufactur
coagul
factor
concentr
also
reduc
arthropodtransmit
virus
wnv
flavivirus
dengu
viru
togavirus
chikungunya
viru
reduct
virus
manufactur
clot
factor
concentr
also
demonstr
use
model
virus
valid
data
demonstr
measur
current
taken
also
relev
emerg
virus
combin
inactiv
remov
method
addit
donat
screen
essenti
elimin
transmiss
virus
princip
concern
name
hav
hbv
hcv
hiv
shown
valid
studi
strategi
involv
differ
step
inactiv
remov
optim
target
virus
differ
physicochem
properti
instanc
although
sd
highli
effect
envelop
virus
ineffect
nonenvelop
virus
eg
hav
thu
second
step
often
dri
heat
lyophil
product
implement
procedur
purif
concentr
desir
protein
usual
less
effect
viru
remov
dedic
reduct
step
inactiv
heat
sd
treatment
remov
viru
filtrat
diagnost
techniqu
advanc
emerg
pathogen
may
identifi
genom
may
detect
final
product
eg
depend
manufactur
process
method
employ
make
extrem
like
new
pathogen
would
inactiv
remov
high
degre
dilig
must
maintain
immun
globulin
plasma
product
inhibitor
esteras
inhibitor
subject
similar
pathogen
reduct
measur
addit
low
ph
util
immun
globulin
product
inactiv
certain
virus
thu
high
safeti
record
observ
product
recent
year
albumin
alway
pasteur
prevent
pathogen
transmiss
product
similar
freshfrozen
plasma
ffp
pool
treat
sd
avail
europ
recent
licens
unit
state
octapla
envelop
virus
effect
inactiv
sd
treatment
chromatograph
method
reduc
prion
transmiss
potenti
product
reli
test
donat
protect
nonenvelop
viru
specif
hav
recent
hepat
e
viru
improv
viru
safeti
compar
ffp
base
sole
reduct
observ
sd
method
blood
product
past
year
fear
potenti
infect
introduct
recombin
factor
product
fuel
shift
toward
recombin
product
first
choic
treatment
patient
hemophilia
howev
opinion
role
recombin
plasmaderiv
concentr
treatment
vari
unit
kingdom
hemophilia
center
director
organ
recommend
recombin
product
patient
hemophilia
wherea
european
countri
recommend
first
choic
children
contrast
germani
austria
clear
recommend
use
recombin
factor
concentr
patient
hemophilia
furthermor
patient
factor
defici
recombin
product
current
avail
eg
von
willebrand
diseas
must
use
plasmaderiv
concentr
physician
current
fewer
safeti
concern
use
plasmaderiv
product
past
fact
fviii
consumpt
approxim
f
ix
consumpt
germani
plasmaderiv
patient
hemophilia
inhibitor
fviii
plasmaderiv
fviii
product
contain
vwf
wide
use
secondlin
treatment
immun
toler
induct
due
improv
comprehens
pathogen
reduct
step
physician
patient
confid
safeti
plasmaderiv
product
treatment
bleed
disord
